#1 Clinical Trials Search in Europe

Leniolisib Phosphate

This article explores the use of Leniolisib Phosphate in clinical trials for treating Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS). APDS is a rare genetic disorder affecting the immune system. Leniolisib Phosphate, a novel drug, is being studied in various trials to assess its safety, efficacy, and optimal dosing in both adult and pediatric patients with APDS.

Table of Contents

What is Leniolisib?

Leniolisib (also known as CDZ173 or Joenja) is a new medication being developed to treat a rare genetic condition called Activated PI3K Delta Syndrome (APDS)[1]. It is a small molecule that works by inhibiting a specific enzyme in the body[2].

What is Activated PI3K Delta Syndrome (APDS)?

Activated PI3K Delta Syndrome (APDS) is a rare genetic disorder that affects the immune system. People with APDS have mutations in genes that control an enzyme called PI3K delta. These mutations cause the enzyme to be overactive, leading to problems with the immune system[1].

Symptoms of APDS can include:

  • Frequent infections, especially in the ears, sinuses, and lungs
  • Enlarged lymph nodes and spleen
  • Difficulty fighting infections
  • Increased risk of certain cancers

How Leniolisib Works

Leniolisib is designed to target and inhibit the overactive PI3K delta enzyme in people with APDS. By reducing the activity of this enzyme, leniolisib aims to help restore normal immune function and reduce symptoms of the disease[2].

Clinical Trials of Leniolisib

Several clinical trials are being conducted to evaluate the safety and effectiveness of leniolisib in patients with APDS:

Study in Children Aged 1 to 6 Years

A Phase III study is evaluating leniolisib in children aged 1 to 6 years with APDS. This study aims to assess the safety, how the drug moves through the body (pharmacokinetics), how it affects the body (pharmacodynamics), and its effectiveness[1].

Study in Children Aged 4 to 11 Years

Another Phase III study is looking at leniolisib in children aged 4 to 11 years with APDS. This study also focuses on safety, pharmacokinetics, pharmacodynamics, and efficacy[4].

Study in Patients with Impaired Liver Function

A Phase I study is investigating how leniolisib affects patients with impaired liver function compared to those with normal liver function[2].

Bioavailability Study

A study is comparing different doses and formulations of leniolisib to understand how well the body absorbs and processes the drug[3].

Dosage and Administration

Leniolisib is taken orally, typically twice a day. The dosage is based on the patient’s weight:

  • For children weighing 8 to <10 kg: 10 mg twice daily
  • For children weighing 10 to <13 kg: 15 mg twice daily
  • For children weighing 13 to <19 kg: 20 mg twice daily
  • For children weighing 19 to <27 kg: 30 mg twice daily
  • For children weighing 27 to <38 kg: 40 mg twice daily
  • For children weighing 38 to 44 kg: 50 mg twice daily
  • For patients weighing ≥45 kg: 70 mg twice daily[1][4]

The medication comes in various forms, including film-coated tablets and film-coated granules in single-dose containers[3].

Safety and Side Effects

The clinical trials are closely monitoring the safety of leniolisib. Researchers are looking at:

  • Side effects that occur during treatment
  • Changes in laboratory test results (blood and urine tests)
  • Changes in vital signs (like blood pressure and heart rate)
  • Changes in physical examinations
  • Changes in electrocardiograms (ECGs, which measure heart activity)
  • Effects on growth and development in children[1][4]

As with any medication, leniolisib may cause side effects. The full range of potential side effects is still being studied. Patients in clinical trials are closely monitored for any adverse reactions.

Conclusion

Leniolisib represents a promising new treatment option for people with Activated PI3K Delta Syndrome (APDS). By targeting the underlying cause of the disease, it has the potential to improve immune function and reduce symptoms in patients with this rare genetic disorder. However, as the drug is still in clinical trials, more research is needed to fully understand its effectiveness and long-term safety profile. Patients with APDS should consult with their healthcare providers to learn more about leniolisib and whether it might be an appropriate treatment option for them.

Aspect Details
Drug Name Leniolisib Phosphate
Target Condition Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS)
Trial Phases Phase I, Phase III
Age Groups Studied 1-6 years, 4-11 years, adults
Dosage Forms Film-coated tablets, Film-coated granules
Dosing Strategy Weight-based, twice daily (BID)
Primary Objectives Safety, Efficacy, Pharmacokinetics, Optimal dosing
Key Endpoints Reduction in lymphoproliferation, Immunophenotype normalization, Infection control
Study Designs Open-label, Single-arm, Long-term extensions
Special Considerations Pediatric formulations, Hepatic impairment studies

FAQ

  • What is Leniolisib Phosphate? Leniolisib Phosphate is a small molecule oral inhibitor of p110δ, designed to treat Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS). It's being studied in clinical trials for its potential to manage symptoms and complications of APDS in both adults and children.
  • What age groups are being studied in these clinical trials? The clinical trials are studying a wide range of age groups. There are trials for adults, as well as pediatric studies focusing on children aged 1-6 years, 4-11 years, and adolescents up to 18 years old. This comprehensive approach aims to determine the safety and efficacy of Leniolisib across different age groups affected by APDS.
  • What are the main objectives of these clinical trials? The main objectives of these trials include assessing the safety and tolerability of Leniolisib, evaluating its efficacy in reducing APDS symptoms, studying its pharmacokinetics (how the drug moves through the body), and determining the appropriate dosing for different age groups and body weights. Long-term safety and efficacy are also being investigated in extension studies.
  • How is Leniolisib administered in these trials? Leniolisib is administered orally in these trials. The dosage varies depending on the patient's age and weight. For example, in pediatric trials, weight-based dosing is used, ranging from 10 mg to 70 mg, given twice daily (BID). The drug is available in various forms, including film-coated tablets and film-coated granules for younger children.
  • What are some of the key findings or expectations from these trials? While specific results are not provided in the given information, the trials are expected to provide crucial data on Leniolisib's effectiveness in managing APDS symptoms, its safety profile, and optimal dosing strategies. The studies aim to show improvements in lymphoproliferation, infection rates, and overall quality of life for patients with APDS. Long-term safety and efficacy data are also being collected to support the potential use of Leniolisib as a treatment for APDS.

Ongoing Clinical Trials on Leniolisib Phosphate

  • Long-term safety and effectiveness study of leniolisib for patients with primary immunodeficiency and immune system problems

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • A Study of Leniolisib Safety and Effectiveness for Immune System Problems in Patients with Common Variable Immunodeficiency

    Not recruiting

    2 1 1
    Investigated drugs:
    Spain

  • Study on the Effects of Leniolisib in Patients with Activated Phosphoinositide 3-Kinase Delta Syndrome

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effects of Leniolisib in Children Aged 1 to 6 with Activated PI3K Delta Syndrome (APDS)

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal Spain

  • Study of Leniolisib for Children Aged 4 to 11 with Activated PI3K Delta Syndrome

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS): A rare genetic disorder affecting the immune system, characterized by recurrent infections, lymphoproliferation, and other immune-related complications.
  • Leniolisib Phosphate: A small molecule oral inhibitor of p110δ, designed to treat APDS by targeting the underlying genetic cause of the condition.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and relationship between drug concentration and effect.
  • Lymphoproliferation: Abnormal growth or increased production of lymphocytes, a type of white blood cell, which can lead to enlarged lymph nodes or organs.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Film-coated tablet: A solid dosage form of medication that is coated with a thin layer to make it easier to swallow or to control its release in the body.
  • Film-coated granules: Small particles of medication that are coated with a thin film, often used for pediatric formulations or for patients who have difficulty swallowing tablets.
  • BID: Latin abbreviation for 'bis in die', meaning twice a day, used in prescriptions and dosing instructions.
  • Immunophenotype: The characteristic set of proteins expressed on the surface of immune cells, used to identify and classify different types of cells.
  • Mammalian target of rapamycin (mTOR): A protein that regulates cell growth, proliferation, and survival, often involved in immune system function.
  • Naïve B cells: B lymphocytes that have not yet been exposed to an antigen, important for maintaining a diverse immune response capability.
  • Cytochrome P450 (CYP): A family of enzymes involved in drug metabolism in the body, particularly important for understanding drug interactions and metabolism.
  • Child-Pugh Classification: A scoring system used to assess the prognosis of chronic liver disease and cirrhosis, often used to determine if patients with liver impairment can participate in drug trials.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-leniolisib-in-children-aged-1-to-6-with-activated-pi3k-delta-syndrome-apds/
  2. http://clinicaltrials.eu/trial/study-on-leniolisib-for-patients-with-activated-phosphoinositide-3-kinase-delta-syndrome-and-impaired-liver-function/
  3. http://clinicaltrials.eu/trial-id/2023-508880-61-00
  4. http://clinicaltrials.eu/trial/study-of-leniolisib-for-children-aged-4-to-11-with-activated-pi3k-delta-syndrome/